IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy

Summary

Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets

Eligibility

Inclusion Criteria:

* Patients aged 18 years or older, male or female.
* Willing to participate in the study and having signed a written informed consent form.
* Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.
* Affiliated with a social security system or benefiting from such a system.

Exclusion Criteria:

* Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.
* Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.
* History of solid organ transplantation or hematopoietic stem cell transplantation.
* Pregnant or breastfeeding women.

Conditions3

Browse More Trials